Innovation in Cardiovascular Disease Management: The Impact of PCSK9 Inhibitors

The Conference Board of Canada, July 19, 2017 at 2:00 PM EST
Live Webinar by The Conference Board of Canada

Cardiovascular disease (CVD) prevalence incurs significant costs to governments and society in the form of hospitalizations, disease management, and lost productivity. Also, some individuals are at increased risk of a first or repeat CVD event due to high LDL cholesterol (LDL-C) levels. A new medication category—proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)—can effectively manage dyslipidemia (high cholesterol) in patients at high risk for cardiovascular disease.

In this 60-minute webinar, Isabelle Gagnon-Arpin will present key findings of the 2017 Conference Board of Canada report Reducing Cardiovascular Disease in Canada: The Impact of PCSK9 Inhibitors in High-Risk Populations. Discover why PCSK9i, recommended by Canadian guidelines for the treatment of dyslipidemia in high-risk patients, can lead to billions of dollars in direct cost savings to the Canadian health care system and indirect cost savings from lost productivity due to premature mortality and hospitalizations.

About Isabelle

Isabelle Gagnon-ArpinIsabelle Gagnon-Arpin is a Senior Research Associate in the Conference Board’s Health Economics and Policy group. She has over eight years of experience conducting research and analyzing health and social services data within a range of settings spanning academia, federal and provincial government, private and not-for-profit organizations. Since joining the Conference Board in January 2016, Isabelle has been leading research projects and providing expertise in epidemiology, health economics and public policy.

Have questions before you buy?

Learn what our webinars can offer you

 

What happens after you register?

Image showing webinar satisfaction scores

Related Research

Register for this webinar